Across TCGA pan-cancer cohorts, ZC3HAV1L Mutation is linked to patient survival in 2 of 34 cancer types, making it a survival-associated ZC3HAV1L data layer compared with 26 for mass-spec protein and 6 for mass-spec protein.
The strongest signal is observed in lymphoid neoplasm diffuse large b-cell lymphoma (DLBC), where higher ZC3HAV1L Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated ZC3HAV1L expression acts as an unfavorable survival marker.
DLBC and GBM are the cancer types where ZC3HAV1L Mutation most reproducibly stratifies survival.